1. Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells.
- Author
-
Shen YC, Shih HJ, Lin CC, Huang SH, Wu SC, Hsiao CH, Chiu SC, Cho DY, Chang CP, Pan Y, and Shih PH
- Subjects
- Chemoradiotherapy, Docetaxel pharmacology, Humans, Lymphocyte Count, Male, Cytokine-Induced Killer Cells, Neoplasms, Second Primary, Prostatic Neoplasms therapy
- Abstract
Background/aim: Prostate cancer (PC) is one of the major diseases that affects male health and ranks as the second most frequent cancer in men worldwide. Although most newly-diagnosed PCs are well-differentiated tumors with a high cure probability, there are some patients with aggressive malignancies that show potential for recurrence and metastasis. Cytotoxic T lymphocytes are a specific immune effector cell population that mediates immune responses against cancer., Materials and Methods: In the present study, the cytotoxicity of peripheral blood mononuclear cells (PBMCs)-derived γδ T cells and cytokine-induced killer (CIK) cells in combination with chemoradiotherapy against PC cells was evaluated using Alamar blue cell viability and cell membrane permeability assays., Results: Advanced PC-3 cells, which were more resistant to docetaxel (Doc), also showed higher viability following pretreatment with radiation. The cell proliferation inhibition was significantly increased upon additional γδ T or CIK treatment. Furthermore, the proportion of apoptotic cells was significantly (p<0.05) increased in the Doc-γδ T cell co-treatment group as compared with the Doc or γδ T cell treated alone group., Conclusion: γδ T cell therapy may provide additional benefit compared to traditional chemoradiotherapy for PC treatment., (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF